When there is substantial uncertainty about a new product’s expected value, stakeholders may have strong reasons to consider performance-based contracts. One of the hardest tasks in crafting such contracts is … Read More
NPR: “A Search For New Ways To Pay For Drugs That Cost A Mint”
Installment plans and refunds for treatments that don’t work are two options getting more attention as ultra-expensive therapies become more common. The financial strains will only grow. Read and hear … Read More
FoCUS Design Lab
Invitation-only Design Lab to further discussions/implementation from the April 2018 Design Lab
Cell & Gene Meeting on the Mesa
Colin Young, FoCUS, presenting a poster on Pipeline Research
American Society of Gene & Cell Therapy Value Summit
Mark TrusheimASGCT Value Summit
Role of COE networks in curative cellular oncology therapies
COE networks currently play an important role in the delivery of care for specialized service lines, including but not limited to solid organ transplantation (SOT), hematopoietic cell transplantation (HCT) and … Read More
FoCUS Research Team interviewed for article on Innovating Payment Models
The leads of the FoCUS Research Teams, Strategic Director Mark Trusheim, Research Advisor Casey Quinn, Director of Simulation & Policy Research Daniel Mytelka, and Director of Drug Development Pipeline Research … Read More
Designing financial solutions to ensure affordable access to cures
The reimbursement of emerging durable/potentially curative cell and gene therapies is likely to be a challenge for the US healthcare market. Considering the pricing of cell- and gene-based therapies approved … Read More
FoCUS responds to HHS “Blueprint” Request for Information
Federal initiative seeks to make access to innovative therapies wider and more financially sustainable On May 16, 2018 the US Department of Health and Human Services (HHS) published a … Read More
Stop-Loss Insurance or Reinsurance for Multiyear Contracts
In previous Research Briefs, we have discussed challenges faced by payers when contemplating using multiyear performance-based contracts. In this brief, we extend the discussion to include additional difficulties that may … Read More